There are currently 90 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
NCT05012631
Recruiting
This study is a pilot, phase II, open-label study of the angiotensin II receptor blocker, losartan, in patients with Sickle Cell Disease (SCD) 6 years or older for 12 months. The investigators will enroll 24 patients with SCD over the course of 1 year with a goal to complete all study procedures in 2 years. The short-term goal is to obtain clinical pilot data regarding the safety and efficacy of losartan in stabilizing or decreasing extracellular volume fraction (ECV) after 12 months of therapy.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
01/27/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Sickle Cell Disease, Diffuse Myocardial Fibrosis
Register for Updates
Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
NCT02824471
Recruiting
'Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell membrane properties, shape, and density, and subsequent critical changes in inflammatory cell and endothelial cell function. Our goal is to understand the impact of CMA abnormalities in SCD, by interrogating a number of reco... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/11/2024
Locations: University Hospitals Case Medical Center, Cleveland, Ohio
Conditions: Sickle Cell Disease
Register for Updates
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
NCT04093986
Recruiting
The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.
Gender:
ALL
Ages:
All
Trial Updated:
03/09/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)
NCT05457790
Recruiting
Research Type: Clinical Trial Background: People with sickle cell disease (SCD) have many health challenges. Also, they often have trouble sleeping. Acceptance and commitment therapy (ACT) might help people with SCD to improve their sleep problems. Objective: To see how well ACT works in people with SCD and sleep problems and to find out how they feel about it. Eligibility: People between the ages of 18 and 55 with SCD and trouble sleeping. Design: The study is remote. Participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Sickle Cell Anemia, Insomnia, Sleeplessness, Transient Insomnia, Nonorganic Insomnia, Chronic Insomnia
Register for Updates
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
NCT04819841
Recruiting
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
04/10/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +2 locations
Conditions: Sickle Cell Disease
Register for Updates
Ultrasound Acute Chest Syndrome Sickle Cell Disease
NCT06880679
Recruiting
Feasibility and reliability of ultrasound in the inpatient hematology setting.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
04/09/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Acute Chest Syndrome, Sickle Cell Disease
Register for Updates
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822
Recruiting
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
Gender:
ALL
Ages:
Between 6 months and 100 years
Trial Updated:
04/09/2025
Locations: University Of Alabama, Birmingham, Alabama +28 locations
Conditions: Sickle Cell Disease
Register for Updates
A Research Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/09/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +158 locations
Conditions: Sickle Cell Disease
Register for Updates
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
NCT06313398
Recruiting
Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how long RBCs survive in people with SCD and other blood disorders before and after treatment compared to those who had a bone marrow transplant. Objective: To learn how long RBCs survive in the body in pe... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Thalassemia, Hemoglobinopathy
Register for Updates
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
NCT04484272
Recruiting
Our long-term goal is to reduce stress and improve sickle cell disease (SCD) pain control with less opioid use through an intervention with self-management relaxation/distraction exercises (RDE), named You Cope, We Support (YCWS). Americans living with SCD suffer recurrent episodes of acute and chronic pain, both of which are exacerbated by stress. Building on the successes of our prior formative studies, we now propose a well-designed, appropriately powered study to test efficacy of YCWS on out... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/02/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Sickle Cell Disease
Register for Updates
Tocilizumab for Acute Chest Syndrome
NCT05640271
Recruiting
The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with chimeric antigen receptor T-cell (CAR-T) therapy, and it is also authorized for treatment of COVID-19. Since IL-6 levels are elevated in the sputum of patients with acute chest syndrome, the investigator... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Sickle Cell Disease, Acute Chest Syndrome
Register for Updates
Blood Sampling for Research Related to Sickle Cell Disease
NCT00542230
Recruiting
This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body. The purpose of the study is to collect a variety of blood samples that may then be used to investigate advances and potential new drug treatments for sickle cell disease. Volunteers mu... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Register for Updates